SLRN Overview
Upcoming Projects (SLRN)
-
Evaluating the Phase 2 Data and Phase 3 Design for Lonigutamab in Thyroid Eye Disease from Acelyrin, Inc.
Ticker: SLRN
Execute By: Jul 31, 2025
Executed Projects (SLRN)
-
Discussing Acelyrin Inc's Phase 2 data and Phase 3 design for Lonigutamab in the treatment of thyroid eye disease.
Tickers: SLRN, AMGN, VRDN
Executed On: Mar 05, 2025 at 11:00 AM EST -
Investigating the Phase 2b/3 clinical trial data of Izokibep for psoriatic arthritis.
Ticker: SLRN
Executed On: Apr 11, 2024 at 05:00 PM EDT -
Discussing ACELYRIN's Izokibep and its potential in HS (Hidradenitis suppurativa) and PsA (Psoriatic Arthritis), compared to other agents including other IL-17s
Ticker: SLRN
Executed On: Aug 09, 2023 at 02:00 PM EDT -
Discussing the potential of ACELYRIN's Izokibep in psoriatic arthritis with a rheumatologist.
Ticker: SLRN
Executed On: May 16, 2023 at 09:30 AM EDT
Upcoming & Overdue Catalysts (SLRN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (SLRN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
